Brief: Scope Fluidics SPV Signs Deal To Assess Clinical Effectiveness Of PCR|ONE Panel SARS-CoV-2
17/08/2020 09:27
Aug 17 (Reuters) - Scope Fluidics SA SCPP.WA :
* SAYS ITS SPV SIGNS DEAL WITH KRZYSZTOF PYRC TO ASSESS
CLINICAL
EFFECTIVENESS OF PCR|ONE PANEL SARS-COV-2 UNDER FDA EMERGENCY
USE AUTHORISATION PROCEDURE
Source text for Eikon: ID:nEM6pmll2a
Further company coverage: SCPP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Scope Fluidics SA
See all newsBrief: Scope Fluidics' EDOCERA Project Meets Second Goal Of Developing Prototype Of Device For Detecting Stroke Symptoms
Brief: Scope Fluidics Q2 Net Loss At 10.1 Million Zlotys
Brief: Scope Fluidics Unit Signs Deal With Poland's PARP For Up To 14.4 Mln Zlotys In Funding For HYBOLIC Project
Brief: Scope Fluidics Says FDA Certification For UNI FAST Panel Planned For Second Half Of 2027
Brief: Scope Fluidics Extends Deadline For First Goal In Hybolic Project